ClinicalTrials.gg
RecruitingNCT07847541Updated Sep 29, 2026

Clinical Evaluation of Botulinum Toxin a in the Management of Temporomandibular Myofascial Pain

A Phase 2 interventional study of Botulinum Toxin Type A (BoNT-A) and 0.9% Normal Saline (Placebo) in Temporomandibular Disorder, sponsored by Riphah International University. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Riphah International University · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing botulinum toxin type A in Temporomandibular Joint Disorders — 3 open to participants now, 3 under way, none of them phase 3. botulinum toxin type A · Temporomandibular Joint Disorders.

Planned enrollment
Largest of 11
118 · median 72
Started
2026
with 2 others
Phase 2
2 of 11
2 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Riphah International University

Among the 11 studies testing botulinum toxin type A in Temporomandibular Joint Disorders, this one has the largest planned enrollment, is one of 3 that started in 2026, is one of 2 in phase 2, and was the 11th registered.

Temporomandibular Joint Disorders

593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.

Browse Temporomandibular Joint Disorders studies →

Open to participants now

3 of the 11 studies testing botulinum toxin type A in Temporomandibular Joint Disorders are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About botulinum toxin type A

botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 75 Temporomandibular Joint Disorders studies recruiting now, 26 (35%) set no upper age limit and 45 (60%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing botulinum toxin type A in Temporomandibular Joint Disorders, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effectiveness of botulinum toxin type A (BoNT-A) in patients with temporomandibular myofascial pain who have not improved after at least 3 months of conservative treatment.

Eligible patients aged 18-60 years will be randomly assigned to one of two groups:

  • Intervention group: Intramuscular injection of 100 U BoNT-A into the bilateral masseter and temporalis muscles.
  • Control group: Intramuscular injection of 0.9% normal saline (placebo) using the same technique.

The primary outcomes will be:

  • Pain intensity, measured using a 0-10 pain scale (VAS/NRS).
  • Maximum mouth opening (maximal interincisal distance), measured in millimetres.

Assessments will be performed before treatment (baseline) and at 1 week, 1 month, and 3 months after injection. The study will also monitor adverse events associated with the injections.

The aim is to determine whether BoNT-A provides greater pain relief and improved mouth opening compared with placebo in patients with temporomandibular myofascial pain. The findings may help support the use of BoNT-A as a treatment option for patients who do not respond to conventional therapy and provide valuable evidence for clinical practice in Pakista

Read the detailed description

Temporomandibular disorders (TMDs) are a group of musculoskeletal and joint issues that affect the temporomandibular joint (TMJ), masticatory muscles, and associated structures. Common patient presentations that can significantly affect quality of life include pain, joint sounds, limited mouth opening, headaches, earaches, and functional impairment (1,2). The multiple causes of TMD, which include parafunctional habits like bruxism, internal derangements, trauma, and myofascial dysfunction, make diagnosis and therapy challenging (3,4).

Physical therapy, occlusal splints, muscle relaxants, and nonsteroidal anti-inflammatory drugs (NSAIDs) remain the primary line of conservative treatment (4). However, some patients with myofascial pain do not react well to conventional therapeutic methods, necessitating other approaches (5). The neurotoxin botulinum toxin type A (BoNT-A) blocks the release of acetylcholine at the neuromuscular junction, resulting in muscle relaxation and temporary chemodenervation (6). Numerous clinical studies have demonstrated that BoNT-A improves jaw function, reduces the intensity of discomfort, and increases maximal interincisal distance in individuals with myofascial TMD (5-7). Even though there is noticeable pain relief, other trials show differing degrees of improvement in mouth opening, therefore the evidence is still inconclusive (6,7).

Given these disagreements, more randomized controlled trials (RCTs) are required to establish consistent treatment recommendations regarding dosage, injection sites, and follow-up schedules. The lack of local data from Pakistan about the use of BoNT-A in TMD therapy emphasizes the need for population-specific evidence.

Objectives:

To evaluate the effectiveness of botulinum toxin type A (BoNT-A) in patients with temporomandibular myofascial pain, by assessing changes in pain intensity and maximal interincisal distance compared with placebo.

03

Conditions studied

  • Temporomandibular Disorder

Keywords

  • Temporomandibular Myofascial Pain
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of TMD, no relief with conservative therapy after at least three months.
  • Clinical diagnosis of bilateral arthrogenous disorder and myalgia.
  • Moreover, TMD can be confirmed by diagnosis through MRI and CT examinations
  • Pregnancy or lactation.
  • Previous mandible or significant facial trauma.
  • History of prior TMD treatment or cosmetic treatments of the face with BoNT/A.
  • Any to BoNT/A as outlined in the XEOMIN package insert.

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
118 participants (estimated)

Study arms

  • Experimental
    Botulinum Toxin Type A (BoNT-A)

    Drug: Botulinum Toxin Type A (BoNT-A)

  • Placebo comparator
    Placebo (0.9% Normal Saline)

    Drug: 0.9% Normal Saline (Placebo)

Interventions

  • Participants will receive a total dose of 100 units of Botulinum Toxin Type A (BoNT-A) administered by intramuscular injection into the bilateral masseter and temporalis muscles (25 U per side in each muscle). The injections will be performed using a 31G × 12 mm needle. Participants will be followed at 1 week, 1 month, and 3 months to assess pain intensity and maximal interincisal mouth opening.

  • Drug0.9% Normal Saline (Placebo)

    Participants will receive 0.9% normal saline by intramuscular injection into the bilateral masseter and temporalis muscles using the same injection technique, volume, and follow-up schedule as the experimental group. The placebo is used to maintain blinding and serve as the comparator.

06

What researchers measure

Primary outcomes

  1. Pain Intensity Numerical Rating Scale

    Changes in pain intensity can be measured using various scales, such as the 11-point Pain Intensity Numerical Rating Scale (PI-NRS), where 0=no pain and 10=worst possible pain. The PI-NRS is commonly used to assess pain intensity in chronic pain management. However, interpreting the clinical importance of changes from baseline on this scale can be challenging. Studies have estimated a clinically important difference on the PI-NRS by relating it to global assessments of change in multiple studies of chronic pain.

    Time frame: 1 week, 1 month, and 3 months after injection.

  2. Change in maximal interincisal mouth opening (MIO)

    The maximum interincisal distance (MID) is a crucial measurement for assessing the function of the temporomandibular joint (TMJ) and the masticatory muscles. It is measured by the distance between the upper and lower incisors when the mouth is fully opened. This measurement is particularly important in evaluating TMJ disorders and can indicate the health of the jaw and its associated muscles.

    Time frame: 1 week, 1 month, and 3 months after injection.

Secondary outcomes

  1. Incidence of adverse events

    Incidence of adverse events

    Time frame: hroughout the 3-month follow-up period.

  2. Pain during mandibular movements

    Pain during mandibular movements

    Time frame: 1 week, 1 month, and 3 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.

Of 14 phase 2 interventional studies under Temporomandibular Joint Disorders, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 39. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2026
First posted
Sep 29, 2026
StartActual
Aug 15, 2026
Primary completionEst.
Dec 15, 2026
CompletionEst.
Dec 15, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847541
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Aug 15, 2026
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Sep 29, 2026

Study contacts

Muhammad Sohaib Arshad
Contact
muhammadsohaibarshad542@gmail.com
+923345635938
Uzair Luqman, FCPS
principal investigator · Riphah International University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion